AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
Last Of Three Phase III Readouts Also Positive
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.
